CO6541545A2 - Compuestos de espiropiperidina como antagonistas del receptor orl-1 - Google Patents

Compuestos de espiropiperidina como antagonistas del receptor orl-1

Info

Publication number
CO6541545A2
CO6541545A2 CO12073055A CO12073055A CO6541545A2 CO 6541545 A2 CO6541545 A2 CO 6541545A2 CO 12073055 A CO12073055 A CO 12073055A CO 12073055 A CO12073055 A CO 12073055A CO 6541545 A2 CO6541545 A2 CO 6541545A2
Authority
CO
Colombia
Prior art keywords
orl
compounds
spyropiperidine
antrogonists
receiver
Prior art date
Application number
CO12073055A
Other languages
English (en)
Inventor
Collado Ana Belen Benito
Buezo Nuria Diaz
Escribano Miguel Angel Toledo
Concepcion Pedregal-Tercero
Grau Maria Angeles Martinez
Blanco Celia Lafuente
Aguado Alma Maria Jimenz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6541545A2 publication Critical patent/CO6541545A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos derivados de espiropiperidina de la fórmula:Así corno a sus métodos de obtención, y composiciones farmacéuticas donde puedan estar presentes actuando como antagonistas del receptor ORL-1, las cuales tienen aplicación en el tratamiento de enfermedades mediadas por la actividad de dicho receptor, tales como: depresión, migraña y/o obesidad.
CO12073055A 2009-11-16 2012-05-04 Compuestos de espiropiperidina como antagonistas del receptor orl-1 CO6541545A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
CO6541545A2 true CO6541545A2 (es) 2012-10-16

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12073055A CO6541545A2 (es) 2009-11-16 2012-05-04 Compuestos de espiropiperidina como antagonistas del receptor orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (es)
EP (1) EP2501703B1 (es)
JP (1) JP5680101B2 (es)
KR (1) KR101363830B1 (es)
CN (1) CN102612520B (es)
AR (1) AR078863A1 (es)
AU (1) AU2010319581C1 (es)
CA (1) CA2796161C (es)
CO (1) CO6541545A2 (es)
CR (1) CR20130087A (es)
DK (1) DK2501703T3 (es)
DO (1) DOP2012000135A (es)
EA (1) EA020848B1 (es)
EC (1) ECSP12011902A (es)
ES (1) ES2435814T3 (es)
HK (1) HK1169988A1 (es)
HN (1) HN2012001011A (es)
HR (1) HRP20130967T1 (es)
IL (1) IL219370A (es)
JO (1) JO2887B1 (es)
MA (1) MA33751B1 (es)
ME (1) ME01537B (es)
MX (1) MX2012005691A (es)
MY (1) MY160665A (es)
NZ (1) NZ600006A (es)
PE (1) PE20121430A1 (es)
PL (1) PL2501703T3 (es)
PT (1) PT2501703E (es)
RS (1) RS53018B (es)
SI (1) SI2501703T1 (es)
TW (1) TWI465453B (es)
UA (1) UA107943C2 (es)
WO (1) WO2011060035A1 (es)
ZA (1) ZA201202967B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102074089B1 (ko) 2009-12-04 2020-02-05 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
TWI582096B (zh) 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之ｏｒｌ－１受體拮抗劑
AU2013326600B2 (en) 2012-10-02 2017-03-30 Bayer Cropscience Ag Heterocyclic compounds as pesticides
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
KR102605854B1 (ko) 2017-02-16 2023-11-23 선오비온 파마슈티컬스 인코포레이티드 조현병의 치료방법
DK3589638T3 (da) 2017-03-02 2021-06-07 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-Gamma-T
SI3589637T1 (sl) * 2017-03-02 2021-08-31 Eli Lilly And Company Spojine uporabne pri inhibiciji ROR-GAMMA-T
EP3661929B1 (en) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
SG11202105769XA (en) 2018-12-17 2021-07-29 Vertex Pharma Inhibitors of apol1 and methods of using same
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
MX2023002269A (es) 2020-08-26 2023-05-16 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos.
AU2023218994A1 (en) * 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP3989247B2 (ja) 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
RU2299883C2 (ru) 2001-04-18 2007-05-27 Эро-Селтик, С.А. Соединения спиропиразола, содержащая их фармацевтическая композиция, способ модуляции опиоидного рецептора и способ лечения с применением таких соединений
WO2002088089A1 (fr) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
US7192964B2 (en) 2001-07-23 2007-03-20 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
EP1470126A1 (en) * 2002-01-28 2004-10-27 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
WO2003095427A1 (fr) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Compose a noyau spiranique
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
AU2003268512A1 (en) 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2005092858A2 (en) * 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
CN102046633B (zh) 2008-03-27 2015-03-25 格吕伦塔尔有限公司 取代的螺环状环己烷衍生物

Also Published As

Publication number Publication date
TW201127841A (en) 2011-08-16
TWI465453B (zh) 2014-12-21
IL219370A0 (en) 2012-06-28
US20110118251A1 (en) 2011-05-19
DK2501703T3 (da) 2013-10-14
KR101363830B1 (ko) 2014-02-14
JO2887B1 (en) 2015-03-15
HN2012001011A (es) 2015-08-31
DOP2012000135A (es) 2012-08-15
RS53018B (en) 2014-04-30
IL219370A (en) 2015-01-29
CN102612520B (zh) 2015-04-08
ECSP12011902A (es) 2012-07-31
ES2435814T3 (es) 2013-12-23
HRP20130967T1 (hr) 2013-11-22
MA33751B1 (fr) 2012-11-01
MX2012005691A (es) 2012-06-13
SI2501703T1 (sl) 2013-11-29
AU2010319581C1 (en) 2014-05-15
PE20121430A1 (es) 2012-10-26
WO2011060035A1 (en) 2011-05-19
EA020848B1 (ru) 2015-02-27
UA107943C2 (en) 2015-03-10
PT2501703E (pt) 2013-11-26
PL2501703T3 (pl) 2014-02-28
CR20130087A (es) 2013-04-17
JP2013510859A (ja) 2013-03-28
JP5680101B2 (ja) 2015-03-04
ME01537B (me) 2014-04-20
AU2010319581A1 (en) 2012-06-07
EP2501703A1 (en) 2012-09-26
US8232289B2 (en) 2012-07-31
HK1169988A1 (en) 2013-02-15
EA201290352A1 (ru) 2012-10-30
NZ600006A (en) 2014-05-30
KR20130026523A (ko) 2013-03-13
CA2796161A1 (en) 2011-05-19
AR078863A1 (es) 2011-12-07
CN102612520A (zh) 2012-07-25
MY160665A (en) 2017-03-15
AU2010319581B2 (en) 2013-12-19
ZA201202967B (en) 2013-09-25
EP2501703B1 (en) 2013-09-18
CA2796161C (en) 2015-03-17

Similar Documents

Publication Publication Date Title
CO6541545A2 (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
NI201300043A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
GT200900231A (es) Moduladores 2-aminopirimidina del receptor de histamina h4
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
PH12015501289B1 (en) Novel benzimidazole derivatives as ep4 antagonists
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
CR11751A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta3
EA201290296A1 (ru) Циклические пептиды, специфичные к рецептору меланокортина-1
CR20110509A (es) Composicion farmaceutica
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
DOP2013000193A (es) Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
BR112012007747B8 (pt) compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
DK3061821T3 (da) Sammensætninger til behandling af forstyrrelser lindret af muskarinreceptoraktivering
GT201200201A (es) Moduladores alostéricos positivos de receptores m1 de la quinolina amida
UY32574A (es) Antagonistas del receptor cxcr3
UY33924A (es) Compuestos de triazolopiridina como inhibidores de cinasa pim
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
CO6781501A2 (es) Dihidrofuranos condensados en calidad de modulares de gpr119 para el tratamiento de diabetes, obesidad y trastornos relacionados
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
CL2013002412A1 (es) Compuestos derivados de (piperidin-4-il)-ureas; composicion farmaceutica; y uso como antagonistas del receptor grelina en el tratamiento de la obesidad, trastornos alimenticios, diabetes, caquexia causada por el cancer, insuficiencia cardiaca congestiva, entre otras.
EA201391618A1 (ru) Комбинация, содержащая умеклидиний и кортикостероид
CR11600A (es) Derivados de indazol
MX2014006433A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2.

Legal Events

Date Code Title Description
FG Application granted